



(12) **DEMANDE DE BREVET CANADIEN**
CANADIAN PATENT APPLICATION
(13) **A1**

(22) Date de dépôt/Filing Date: 2007/03/18
(41) Mise à la disp. pub./Open to Public Insp.: 2007/09/20
(62) Demande originale/Original Application: 2 922 127
(30) Priorité/Priority: 2006/03/16 (US60/782,689)

(51) Cl.Int./Int.Cl. *A61K 38/19* (2006.01),
A61P 37/02 (2006.01)
(71) Demandeur/Applicant:
SYMThera Canada Ltd., CA
(72) Inventeurs/Inventors:
EZERZER, CHAI, IL;
HARRIS, NICHOLAS, IL
(74) Agent: SMART & BIGGAR

(54) Titre : COMBINAISON DE CYTOKINES ET DU RECEPTEUR DE CYTOKINES DESTINEE A MODIFIER LE
FONCTIONNEMENT DU SYSTEME IMMUNITAIRE
(54) Title: COMBINATION OF CYTOKINE AND CYTOKINE RECEPTOR FOR ALTERING IMMUNE SYSTEM
FUNCTIONING

(57) **Abrégé/Abstract:**

The invention provides a pharmaceutical composition including a cytokine and a peptide comprising at least a portion of a chemokine receptor or a c₁ protein coupled receptor. The pharmaceutical composition of the invention may be used for altering immune system functioning, for example, to treat an immune system disorder, such as an autoimmune disease, multiple sclerosis, transplant rejection, psoriasis and asthma. The invention also provides peptides that may be used in the pharmaceutical composition and a method for preparing the pharmaceutical composition of the invention. The invention further provides a method for to treating an immune system disorder, such as an autoimmune disease, multiple sclerosis, transplant rejection, and psoriasis asthma.

ABSTRACT

The invention provides a pharmaceutical composition including a cytokine and a peptide comprising at least a portion of a chemokine receptor or a c₁ protein coupled receptor. The pharmaceutical composition of the invention may be used for altering immune system functioning, for example, to treat an immune system disorder, such as an autoimmune disease, multiple sclerosis, transplant rejection, psoriasis and asthma. The invention also provides peptides that may be used in the pharmaceutical composition and a method for preparing the pharmaceutical composition of the invention. The invention further provides a method for treating an immune system disorder, such as an autoimmune disease, multiple sclerosis, transplant rejection, and psoriasis asthma.

COMBINATION OF CYTOKINE AND CYTOKINE RECEPTOR FOR ALTERING IMMUNE SYSTEM FUNCTIONING

FIELD OF THE INVENTION

This invention relates to peptides which bind cytokines and their use in immune
5 disorders.

BACKGROUND OF THE INVENTION

The following publications are considered relevant for an understanding of the
invention.

10 Anders, H.J., Frink, M., Linde, Y., Banas, B., Wornle, M., Cohen, C.D., Vielhauer,
V., Nelson, P.J., Grone, H.J. and Schlondorff, D. (2003) CC chemokine ligand
5/RANTES chemokine antagonists aggravate glomerulonephritis despite reduction of
glomerular leukocyte infiltration. J Immunol 170, 5658-66.

Attwood, M., Borkakoti, N., Bottomley, G., Conway, E., Cowan, I., Fallowfield,
15 A., Handa, B., Jones, P., Keech, E., Kirtland, S., Williams, G. and Wilson, F. (1996)
Identification and characterisation of an inhibitor of interleukin-8: a receptor based
approach. Bioorganic & Medicinal Chemistry Letters 6, 1869-74.

Attwood, M., Conway, E., Dunsdon, R., Greening, J., Handa, B., Jones, P., Jordan,
S., Keech, E. and Wilson, F. (1997) Peptide based inhibitors of interleukin-8: structural
20 simplification and enhanced potency. Bioorganic & Medicinal Chemistry Letters 7, 429-
32.

Blanpain, C., Migeotte, I., Lee, B., Vakili, J., Doranz, B.J., Govaerts, C., Vassart,
G., Doms, R.W. and Parmentier, M. (1999) CCR5 binds multiple CC-chemokines: MCP-
3 acts as a natural antagonist. Blood 94, 1899-905.

25 Bruhl, H., Cihak, J., Schneider, M.A., Plachy, J., Rupp, T., Wenzel, I., Shakarami,
M., Milz, S., Ellwart, J.W., Stangassinger, M., Schlondorff, D. and Mack, M. (2004) Dual

role of CCR2 during initiation and progression of collagen-induced arthritis: evidence for regulatory activity of CCR2⁺ T cells. *J Immunol* 172, 890-8.

Christen, U. and von Herrath, M.G. (2004) Manipulating the type 1 vs type 2 balance in type 1 diabetes. *Immunol Res* 30, 309-25.

5 Cox, M.A., Jenh, C.H., Gonsiorek, W., Fine, J., Narula, S.K., Zavodny, P.J. and Hipkin, R.W. (2001) Human interferon-inducible 10-kDa protein and human interferon-inducible T cell alpha chemoattractant are allotypic ligands for human CXCR3: differential binding to receptor states. *Mol Pharmacol* 59, 707-15.

10 Dogan, R.N. and Karpus, W.J. (2004) Chemokines and chemokine receptors in autoimmune encephalomyelitis as a model for central nervous system inflammatory disease regulation. *Front Biosci* 9, 1500-5.

Ferreira, A.M., Rollins, B.J., Faunce, D.E., Burns, A.L., Zhu, X. and Dipietro, L.A. (2005) The effect of MCP-1 depletion on chemokine and chemokine-related gene expression: evidence for a complex network in acute inflammation. *Cytokine* 30, 64-71.

15 Fulkerson, P.C., Zimmermann, N., Brandt, E.B., Muntel, E.E., Doepker, M.P., Kavanaugh, J.L., Mishra, A., Witte, D.P., Zhang, H., Farber, J.M., Yang, M., Foster, P.S. and Rothenberg, M.E. (2004) Negative regulation of eosinophil recruitment to the lung by the chemokine monokine induced by IFN-gamma (Mig, CXCL9). *Proc Natl Acad Sci U S A* 101, 1987-92.

20 Gaupp, S., Pitt, D., Kuziel, W.A., Cannella, B. and Raine, C.S. (2003) Experimental autoimmune encephalomyelitis (EAE) in CCR2^(-/-) mice: susceptibility in multiple strains. *Am J Pathol* 162, 139-50.

25 Gayle, R.B., 3rd, Sleath, P.R., Srinivason, S., Birks, C.W., Weerawarna, K.S., Cerretti, D.P., Kozlosky, C.J., Nelson, N., Vanden Bos, T. and Beckmann, M.P. (1993) Importance of the amino terminus of the interleukin-8 receptor in ligand interactions. *J Biol Chem* 268, 7283-9.

Gerard, C. and Rollins, B.J. (2001) Chemokines and disease. *Nat Immunol* 2, 108-15.

Godessart, N. and Kunkel, S.L. (2001). Chemokines in autoimmune disease. *Curr Opin Immunol* 13, 670-5.

Horuk, R. (2003) Development and evaluation of pharmacological agents targeting chemokine receptors. *Methods* 29, 369-75.

5 Kim, M.Y., Byeon, C.W., Hong, K.H., Han, K.H. and Jeong, S. (2005) Inhibition of the angiogenesis by the MCP-1 (monocyte chemoattractant protein-1) binding peptide. *FEBS Lett* 579, 1597-601.

Loetscher, P., Pellegrino, A., Gong, J.H., Mattioli, I., Loetscher, M., Bardi, G., Baggiolini, M. and Clark-Lewis, I. (2001) The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3. *J Biol Chem* 276, 2986-91.

Mackay, C.R. (2001) Chemokines: immunology's high impact factors. *Nat Immunol* 2, 95-101.

Nakajima, H., Sugino, M., Kimura, F., Hanafusa, T., Ikemoto, T. and Shimizu, A. (2004) Decreased CD14+CCR2+ monocytes in active multiple sclerosis. *Neurosci Lett* 15 363, 187-9.

Ogilvie, P., Bardi, G., Clark-Lewis, I., Baggiolini, M. and Uguccioni, M. (2001) Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5. *Blood* 97, 1920-4.

Onuffer, J.J. and Horuk, R. (2002) Chemokines, chemokine receptors and small-molecule antagonists: recent developments. *Trends Pharmacol Sci* 23, 459-67.

20 Petkovic, V., Moghini, C., Paoletti, S., Uguccioni, M. and Gerber, B. (2004a) Eotaxin-3/CCL26 is a natural antagonist for CC chemokine receptors 1 and 5. A human chemokine with a regulatory role. *J Biol Chem* 279, 23357-63.

Petkovic, V., Moghini, C., Paoletti, S., Uguccioni, M. and Gerber, B. (2004b) I-TAC/CXCL11 is a natural antagonist for CCR5. *J Leukoc Biol* 76, 701-8.

25 Proudfoot, A.E., Power, C.A., Rommel, C. and Wells, T.N. (2003) Strategies for chemokine antagonists as therapeutics. *Semin Immunol* 15, 57-65.

Quinones, M.P., Ahuja, S.K., Jimenez, F., Schaefer, J., Garavito, E., Rao, A., Chenuaux, G., Reddick, R.L., Kuziel, W.A. and Ahuja, S.S. (2004) Experimental arthritis

in CC chemokine receptor 2-null mice closely mimics severe human rheumatoid arthritis. J Clin Invest 113, 856-66.

Rossi, D. and Zlotnik, A. (2000) The biology of chemokines and their receptors. Annu Rev Immunol 18, 217-42.

5 Sabroe, I., Peck, M.J., Van Keulen, B.J., Jorritsma, A., Simmons, G., Clapham, P.R., Williams, T.J. and Pease, J.E. (2000) A small molecule antagonist of chemokine receptors CCR1 and CCR3. Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry. J Biol Chem 275, 25985-92.

Schwarz, M.K. and Wells, T.N. (2002) New therapeutics that modulate chemokine
10 networks. Nat Rev Drug Discov 1, 347-58.

Szekanecz, Z., Kim, J. and Koch, A.E. (2003) Chemokines and chemokine receptors in rheumatoid arthritis. Semin Immunol 15, 15-21.

Thomas, M.S., Kunkel, S.L. and Lukacs, N.W. (2002) Differential role of IFN-gamma-inducible protein 10 kDa in a cockroach antigen-induced model of allergic airway
15 hyperreactivity: systemic versus local effects. J Immunol 169, 7045-53.

Thomas, M.S., Kunkel, S.L. and Lukacs, N.W. (2004) Regulation of cockroach antigen-induced allergic airway hyperreactivity by the CXCR3 ligand CXCL9. J Immunol 173, 615-23.

Wells, T.N., Power, C.A., Shaw, J.P. and Proudfoot, A.E. (2006) Chemokine
20 blockers--therapeutics in the making? Trends Pharmacol Sci 27, 41-7.

Xanthou, G., Duchesnes, C.E., Williams, T.J. and Pease, J.E. (2003) CCR3 functional responses are regulated by both CXCR3 and its ligands CXCL9, CXCL10 and CXCL11. Eur J Immunol 33, 2241-50.

Zlotnik, A. and Yoshie, O. (2000) Chemokines: a new classification system and
25 their role in immunity. Immunity 12, 121-7.

www.leaddiscovery.co.uk, February 2005.

Chemokines In Health and Disease

The immune system promotes health by combating foreign pathogens, alleviating intrinsic disease and repairing physical injury. Infected, injured, or otherwise compromised tissues mobilize cells of the immune system by releasing chemo-attractants called chemokines (CKs) into the blood stream. The same CKs induce the activation of leukocytes and direct the differentiation of lymphocytes [Rossi, 2000; Zlotnik, 2000]. The deployment of immune cells is essential, not only to confront pathogenic challenge, but also for immune surveillance and tolerance to "*self*" [Mackay, 2001]. Close to fifty different human CKs and twenty CK receptors (CKRs) respond to multifarious pathogens and disease states. Tight regulatory control of the CK system imparts rapid, measured and apposite responses to the various pathogenic challenges. Of equal importance to health is the control which prevents the immune system from acting against "*self*". An immune response which is inappropriate, excessive, or protracted, relative to the pathogenic insult, if any, will cause injury to healthy tissue. Such aberrant immune responses are responsible for the clinical conditions of multiple sclerosis, inflammatory bowel disease (Crohn's disease, ulcerative colitis), rheumatoid arthritis, psoriasis, asthma and juvenile diabetes, the major and prevalent autoimmune diseases. Experimental studies with animal models of disease [Gerard, 2001; Dogan, 2004; Szekanecz, 2003] and clinical observations [Gerard, 2001; Godessart, 2001] indicated that the levels of CKs and their cognate receptors correlate with specific autoimmune diseases.

Current Treatment of Autoimmune Disease

The etiology of no single autoimmune disease is known, but disease pathology, in every case, is the result of immune cell activity directed against "*self*". It follows, therefore, that the "state of the art" treatment is restricted to the induction and maintenance of disease remission. Multiple sclerosis (MS), the most common cause of neurological disability in young adults, presents with a relapsing-remitting course and is followed by a secondary progressive phase. Steroids are the first choice of treatment to

shorten the duration of relapse and accelerate recovery. Long term treatment, with Non Steroidal Anti Inflammatory Drugs (NSAIDs), is given to maintain, or extend remission. Inflammatory bowel disease (IBD) affects over 1 million Americans today [www.leaddiscovery.co.uk, February 2005.]. Manifested by severe abdominal pain and diarrhea, it is associated with an increased risk of bowel cancer. For patients suffering mild IBD, remission is induced with NSAIDs. Because of the adverse side effects of steroids, they are reserved for patients with moderate to severe disease and for those who do not respond to NSAIDs. When the disease is refractory to steroids, immunosuppressant drugs are used.

10

Established and new treatments of autoimmunity act by modulating and if necessary, suppressing the immune system. Both approaches run the risk of side effects, the short term of which are known, the long term, which cannot always be predicted. The shortcomings of steroids, the first line of treatment for severe MS and IBD are well documented: gastrointestinal, dermatologic, neurological, endocrinological, ophthalmic and metabolic side effects. Remission in MS is “extended” by interferon beta and glatiramer acetate (Copaxone), but drug efficacy, tantamount to a 30% reduction in the frequency of relapse, is offset by severe side effects, such as fatigue, pain and bladder dysfunction. The range of medications extending remission in IBD is wider, but the side effects no less severe. NSAIDs are intolerable to a significant number of IBD patients and the alternatives, the immuno-suppressants 5-AZT and 6-mp, cause severe side effects. Prolonged use of a new generation of antibody drugs, exemplified by Remicade, is beginning to reveal a negative side. Remicade has been linked with tuberculosis, opportunistic infection and the activation of latent MS (Centocor, Inc. 2005). Add to this deteriorating safety profile the high cost and administration by intravenous infusion and this innovative treatment becomes a less than an attractive alternative to tried and tested medications. There is a need for improved medication to treat acute inflammation in disease relapse and provide long term treatment to maintain remission.

25

Chemokine Receptors (CKRs) As Conventional Drug Targets

The CKR, a member of the G-protein Coupled Receptor (GPCR) family, has a drug target pedigree. More than forty five percent of all marketed drugs target GPCRs [Horuk, 2003]. Given that the ligands of GPCRs are low molecular weight peptides (histamine, dopamine, serotonin), it was predicted that CKRs would be tractable targets for small molecule drugs (Proudfoot et al., 2003). The majority of drug candidates targeting CKRs, including those under development and those which have been abandoned, are indeed small molecule inhibitors [Wells, 2006]. Based on steric and energetic considerations [Onuffer, 2002] and empirical studies [Sabroe, 2000], it was proposed that small molecule antagonists of CKRs should be non-competitive inhibitors of CKs that block ligand-receptor interaction by stabilizing the receptor in an inactive conformation.

CKRs are known to interact with both their cognate and with unrelated CK ligands, a phenomenon known as "redundancy". As a functional definition of CK-CKR interaction, a "cognate" CKR - CK pair is defined as a CKR and a CK for which the CKR is activated by nanograms of the CK to induce intracellular signaling (calcium mobilization, kinase and lipase activation). With respect to the same CK-CKR system, an "unrelated" CKR- CK combination is defined as a CKR which requires at least three orders of magnitude more of CK, micrograms, to elicit a positive, negative, or unproductive intracellular response.

The identity of CKRs as GPCRs is an evident advantage for drug development. The atypical involvement of these GPCRs in physiological immunity, however, makes CKRs equivocal drug targets and even a therapeutic liability. Antibodies against the receptor, CCR2, which is expressed by inflammatory T cells and monocytes, were used to treat experimental collagen-induced arthritis [Bruhl, 2004]. The treatment was therapeutic during disease initiation (day 0-15), but deleterious in disease progression (day 21-36). It transpired that a sub-population of regulatory T cells, responsible for immune tolerance, is expanded several fold during the phase of disease progression. The antibodies, by

blocking the CCR2 receptors of regulatory T cells, exacerbated disease symptoms. Inhibition of the same drug target expressed by different cell types, CCR2 in the example, can be therapeutic, or pathologic, depending on the function of the cell expressing the targeted CKR. The CK, RANTES/CCL5* (*CK classification: [Zlotnik, 2000]) and its
 5 cognate receptor, CCR5, are examples of disease-related proteins that are also essential for physiological immunity. Elevated levels of CCL5 and CCR5 correlated with glomerular cell proliferation and macrophage infiltration in experimental glomerulonephritis. CK analogues (Met-RANTES and amino-oxypentane-RANTES), which block the receptor, reduced glomerular cell proliferation and macrophage
 10 infiltration, but aggravated clinical symptoms [Anders, 2003]. The CK analogues were observed to be therapeutic antagonists of leukocyte recruitment, but pathogenic activators of resident macrophages. CKRs, validated GPCR drug targets, are potential therapeutic liabilities as mediators of physiological immunity.

15 CKs and CKRs constitute a network of interacting proteins [Schwarz, 2002]. Drugs directed at individual proteins of a network risk perturbing the network as a whole. It follows, therefore, that when interacting and interdependent proteins of the network are essential for physiological immunity, targeting one of the proteins may affect the overall function of the immune system and so reduce the drug's efficacy. CK gene knock-out has
 20 been the preferred experimental approach to study the physiological consequences of CK network interference. In a comparative study of inflammatory cells from MCP1/CCL2 null mice and their wild type counterparts, it was found that eliminating MCP-1/CCL2 altered immune responses to disease [Ferreira, 2005]. Equivalent tissues and cells from null and wild-type diseased mice showed significant differences in their respective CK
 25 and CK receptor profiles. Network principles were also observed in tissues derived from the MCP-1/CCL2 null mice. Reconstituted expression of MCP-1/CCL2 in macrophages of the CK knock-out mice selectively suppressed the expression of CKs, those specifically induced by MCP-1/CCL2 inactivation. Physiological immunity in genetically

altered animals, as in their wild type counterparts, was dictated by principles of network responses and adaptation.

In experimental animal models of disease, the relevance of networking is most
 5 conspicuous at the cellular level. Experimental autoimmune encephalomyelitis (EAE), a
 rodent model of multiple sclerosis, was used to study the role of CCR2 in disease
 development [Gaupp, 2003]. The recruitment of monocytes and macrophages into the
 CNS was examined in CCR2 knock-out, disease-induced mice. Contrary to what was
 expected, inactivation of CCR2 did not confer resistance to EAE in the mice. CNS lesions
 10 did contain diminished levels of monocytes, proof of impaired monocyte function, but
 also elevated levels of neutrophils. CK (IL-8/CXCL8) and CK receptor (CCR1, CCR5)
 profiles of the experimental mice were found to be consistent with augmented neutrophil
 levels in the lesions. It was proposed that the CK-CKR network of the CCR2 null mice
 responded to disease induction with a "*compensatory*" immune response involving
 15 alternative immune regulator molecules and effector cells. The foregoing example is yet
 another expression of the network principle. Neutralization of a disease-related protein,
 one which is important for physiological processes in general, can elicit a counter
 response, which itself can be pathological. A murine model of experimental arthritis,
 which reproduces the symptoms of severe human rheumatoid arthritis, provided another
 20 illustration of the physiological consequences of network interference [Quinones, 2004].
 CCR2 knock-out mice were used to study the role of the receptor in experimental
 arthritis. The CKR is implicated in disease pathogenesis, therefore, it was not anticipated
 that the phenotype of the CCR2 knock-out mice would be similar to that found in severe
 human arthritis, elevated T cell levels and monocytes and macrophages concentrated in
 25 the inflamed joints. The proffered explanation was that disease in the CKR compromised
 mice stimulated the expression of alternative CKRs to mobilize the inflammatory cells.
 The consequence of perturbing a physiologically essential network, even for therapeutic

effect, can be to elicit compensatory reactions to consolidate, but potentially exacerbate, the status quo.

The CK – CKR axis, despite the "druggable" attributes of GPCRs and their small molecule ligands, is demonstrably problematic as a drug target. It functions as a network of interactive and interdependent regulatory proteins central to physiological immunity. Compensatory and possibly deleterious responses may therefore be the unavoidable consequences of pharmacological intervention in the network.

The Chemokine – Chemokine Receptor Network

A disproportionate number of chemokine (CK) ligands, ill-defined ligand specificity and equivocal CK functionality *in vitro*, were cited as proof of CK "redundancy" and worse still, "promiscuity". Such epithets, although consistent with data at the time, were incompatible with a CK – Chemokine Receptor (CKR) network essential for physiological immunity and pathological autoimmunity. Re-examination of the original data, in the light of subsequent functional studies and structure-activity analyses, reveals physiological relevance in both the ligand to receptor ratio and ostensibly indiscriminate receptor activation. To begin with, CKs, which are agonists of their cognate receptors, were found to be natural antagonists of unrelated receptors, as determined by chemotaxis and Ca^{2+} flux assays. Three agonists of the receptor, CXCR3, MIG/CXCL9, IP10/CXCL10 and I-TAC/CXCL-11, were shown to be antagonists of the unrelated receptor, CCR3 [Loetscher, 2001]. The most potent of the three, I-TAC/CXCL11, was found to be a natural antagonist of CCR5 [Petkovic, 2004]. Eotaxin/CCL11, an agonist of CCR3, was also shown to be an agonist and natural antagonist of the unrelated receptors CCR5 and CCR2, respectively [Ogilvie, 2001]. Another cognate ligand and agonist of CCR3, Eotaxin3/CCL26, was found to be a natural antagonist of unrelated receptors CCR1 and CCR5 [Petkovic, 2004]. MCP3/CCL7, a cognate agonist of receptors CCR1, 2 and 3, was shown to be a natural antagonist of the

receptor, CCR5 [Blanpain, 1999]. The concomitant activation and inhibition of CKRs was interpreted to be a mechanism for regulating the recruitment of functionally discrete sub-populations of leukocytes. To illustrate the point, MIG/CXCL9 and Eotaxin/CCL11, by altering the balance between Th1 and Th2 cells, could determine the course of Allergic Airway Inflammation [Thomas, 2004; Fulkerson, 2004]. MIG/CXCL9 is an agonist of CXCR3, expressed by Th1 cells and an antagonist of CCR3, expressed by Th2 cells. Eotaxin/CCL11, a cognate ligand of CCR3, was also shown to have a high affinity binding site in the unrelated receptor, CXCR3 [Xanthou, 2003]. A refinement of the point, activation/inhibition of CKRs, was regulation of T cell recruitment by differential activation of the same receptor [Thomas, 2002]. IP-10/CXCL10 and MIG/CXCL9, cognate ligands of CXCR3, could respectively enhance, or diminish eosinophil accumulation and airway hyper-reactivity. Cumulative data now show that the disease-related distribution and activities of immune cells are in fact a corollary of CK multiplicity and specificity for diverse CKRs.

Since neither experimental data, nor clinical evidence distinguishes between wild type and disease-related CKs, it is presumably the same chemo-attractants that mobilize the immune cells of physiological and pathological immune responses. CK pathogenicity appears to be the consequence of inordinate, inappropriate and enduring wild-type CK activity, phenomena consistent with CK network deregulation. CK to receptor binding analyses were carried out to elucidate the molecular bases for the regulation of CK – CKR interactions. MIG/CXCL9 and IP-10/CXCL10 bind competitively the receptor CXCR3 but non-competitively with respect to the third related CK, ITAC/CXCL11 [Cox, 2001]. In this example, functionally related CKs were shown to interact with discrete and overlapping sites in their cognate receptor. The anomalous activities of CKs, those of CKs interacting with unrelated receptors, may be more informative about CK network regulation per se. For example, the cognate ligands of CXCR3 inhibited CCR3 functional responses and were observed to displace that receptor's cognate ligand, Eotaxin/CCL11

[Loetscher, 2001]. A more detailed study of the same system disclosed that ITAC/CXCL11, cognate ligand of CXCR3, efficiently displaced Eotaxin/CCL11 from the extra-cellular loops of the latter's receptor, CCR3. Cognate and unrelated ligands, therefore, can share overlapping binding sites within the same receptor [Xanthou, 2003].

5 Another anomalous, but informative observation, concerns Eotaxin/CCL11 and its unrelated receptor, CXCR3. Although Eotaxin/CCL11 is neither an agonist, nor an antagonist of CXCR3 *in vitro*, the receptor has a high-affinity binding site for this CK which can be competitively occupied by ITAC/CXCL11 [Xanthou, 2003].

10 Chemokines As Innovative Drug Targets

An upshot of the molecular structure-activity analyses and binding studies is that receptors comprise CK binding sequences that, given the context, are regulators of CK activity. In the context of the CKR, regulatory elements are potential, but problematic drug targets, because the receptors are essential for physiological immunity.

15 Functional studies and complementary molecular analyses of CK receptors, have disclosed regulatory sequences in the receptors of physiological and disease-related CKs. Anomalous interactions of CKs with unrelated receptors implicate ubiquitous cryptic regulatory sequences important for general CK – CKR network activity. CKR derived
20 CBPs, capable of modifying CK binding activities, are not without precedent. In a study to identify and define receptor sequences responsible for IL-8/CXCL8 and GRO- α /CXCL1 binding, receptor-derived sequences were shown to be competitive inhibitors of CK binding [Gayle, 1993]. A peptide derived from an extra-cellular domain of the same receptor, CXCR1, was found to be an antagonist of the cognate CK, IL-8/CXCL8
25 [Attwood, 1996] and when chemically modified, the peptide was made a stronger inhibitor [Attwood, 1997]. More recently, an MCP1/CCL2 binding peptide, homologous to a sequence in an extra-cellular loop of the CKRs CCR2 and CCR3, was shown to be angiostatic by antagonizing MCP-1/CCL2 binding to CCR2 [Kim, 2005].

Mechanism of Drug Action - Redress Of Immune Imbalance

The pathogenesis of all autoimmune diseases is patently de-regulated and dysfunctional immune activity. A challenge for any therapeutic approach is to manipulate immune processes that, in the same individual, both cause clinical symptoms and protect
 5 against disease. To date, no therapy has met the challenge satisfactorily. Autoimmune diseases are treated with low efficacy drugs which cause significant side effects. Most of the current drugs are small synthetic molecules whose deficiencies appear to derive from their mechanism of action, irreversible inhibition of disease related proteins.

10 Drug candidates targeting CKRs belong to the class of small synthetic molecules [Wells, 2006]. Following from the preceding discussion, drugs of this type are inherently flawed. None can be expected to block and neutralize a CKR with impunity, given the organization of CKs and their receptors as a network which is essential for physiological immunity. The principles of network activity govern immune responses at the molecular
 15 and cellular levels and dictate the outcome, therapeutic, or deleterious, of inhibitory drug activity. The overriding objective of the network is to maintain immune balance, any perturbation of the network eliciting a response to redress the balance. Experimental models of autoimmune disease and clinical evidence provide manifold examples of network activity where disease manifests itself as immune imbalance and health is
 20 restored by redressing the balance. Take, for example, allergen challenge in the lung, which elicits deleterious eosinophils and protective Th1 lymphocytes [Fulkerson, 2004; Thomas, 2002]. Allergen-induced CK, Eotaxin/CCL11, recruits inflammatory eosinophils. At the same time, Th1 cells express the CK, MIG/CXCL9, a natural inhibitor of eosinophils. The inference was that the inflammatory status of the allergic lung was
 25 dictated by competition between positive and negative regulatory CKs, the result of which competition was translated into a balance between Th1 and eosinophilic cells. The clinical symptoms of type 1 diabetes, herpes stromal keratitis and multiple sclerosis, are infection, tipping of the T helper (Th) lymphocyte balance in favor of a type 1 milieu [Christen,

2004]. Support for the hypothesis was provided by the diabetogenic RIP-LCMV mouse model. Type 1 CKs and cytokines were shown to be responsible for the diabetic state of the RIP-LCMV mouse. It was suggested, with qualification, that redressing the immune imbalance by inhibiting the type 1 inducing factors, or administering Type 2 cytokines, could be therapeutic. Immune balance is argued to be a salient determinant of disease progression in relapsing-remitting multiple sclerosis [Nakajima, 2004]. Levels of Th1-related CKs are elevated in the active phase of MS whereas MCP-1/CCL2, reported to induce Th2 reactions, is elevated in remission. An analysis of blood from patients with active MS revealed elevated levels of Th1 lymphocytes and significantly reduced levels of monocytes expressing CCR2, the cognate receptor of MCP-1/CCL2. The results were interpreted as evidence that elevated MCP-1/CCL2 and a subset of peripheral monocytes expressing CCR2, may correct the Th1/Th2 imbalance to create conditions for disease remission.

The Th1 – Th2 dichotomy influences immune balance in physiological immunity and is a determining factor in causing the immune imbalance that is characteristic of autoimmune disease. Under prevailing physiological conditions, Th1 and Th2-like cells are in equilibrium, contributing to the establishment and maintenance of immune balance. Innate and extraneous stimuli induce Th1 and Th2-like immune responses that create new, transient equilibria and immune imbalance. Responses that entail modification of the immune cell repertoire establish a new Th1 – Th2 equilibrium, restoring immune balance. In autoimmune disease, a loss of tolerance is expressed as pathological Th1-Th2 disequilibrium and immune imbalance. In the absence of treatment, resolution of the Th1 – Th2 disequilibrium is transient and an enduring immune imbalance leads to relapse. Effective treatment of an autoimmune disease, therefore, must restore Th1 – Th2 cell equilibrium to redress the immune imbalance for tolerance and disease remission. It follows, therefore, that one way to treat autoimmune disease is to alter the pathogenic equilibrium state. A pharmacological intervention is required to create a new equilibrium

and to redress immune imbalance for tolerance. Its application must be incremental and in keeping with the principles of equilibrium dynamics for maximal therapeutic effect and minimal, detrimental side effects.

5 A recurrent theme in the study of autoimmune disease is the intercalation of physiological immunity with pathological autoimmunity. Evidence has been presented to show that the former state is achieved when immune regulators and effectors are in balance and the latter, disease state, when they are in imbalance. Given that the balance is contingent on a network of regulatory proteins, negation of a protein, albeit disease
10 related, portends imbalance. Efficacy, therefore, must be sought in a drug which modulates and does not negate the disease-related activity of the network-associated protein.

SUMMARY OF THE INVENTION

15 The present invention is based on the novel and unexpected finding that a combination consisting of a chemokine and at least a fragment of a chemokine receptor protein is capable of affecting immune system functioning. The inventors have found that a combination consisting of a chemokine and at least a fragment of a chemokine receptor can affect immune system function in a way that is different from the effect observed
20 when the chemokine or at least, a fragment of the chemokine receptor is administered alone. The pharmaceutical composition of the invention may be used to alter immune system functioning, and thus to treat immune system diseases.

In one aspect, the present invention provides a pharmaceutical composition comprising:

- 25 (a) A cytokine;
- (b) A peptide comprising at least a portion of a cytokine receptor or a G-protein coupled receptor (GPCR); and

(c) A physiologically acceptable carrier.

The cytokine may be a chemokine. If the receptor may is a cytokine receptor it may be a chemokine receptor.

In a preferred embodiment, the peptide of the pharmaceutical composition
 5 comprises at least a portion of an extracellular domain of the receptor. In an even more preferred embodiment, the peptide of the pharmaceutical composition comprises at least a portion of a regulatory sequence of the receptor. The pharmaceutical composition may include a cytokine that, in the absence of the at least a portion of the receptor, is an inflammatory chemokine, a constitutive chemokine or a dual function chemokine. The
 10 peptide may bind to the chemokine.

For example, the chemokine MIG, is expressed at elevated levels in inflammatory conditions and is classified as an inflammatory CK. The peptide *WVFGNAMCK*, referred to herein as "*Peptide 8*" is a fragment of the ECL-2 of human C-C chemokine receptor type 2 (CCR2; Monocyte Chemoattractant Protein 1 receptor). As demonstrated below,
 15 Peptide 8 has a pro-inflammatory effect when administered alone to disease-induced mice, increasing inflammation by 44% compared with disease-induced, untreated animals. However, quite unexpectedly, a combination of MIG and Peptide 8 has an anti-inflammatory effect when administered to disease-induced animals.

As another example, the chemokine RANTES when administered alone to disease
 20 induced mice is pro-inflammatory, and Peptide 8 has a pro-inflammatory effect when administered alone to disease-induced mice. However, a combination of RANTES and Peptide 8 when administered together to disease-induced mice has an anti-inflammatory effect.

While not wishing to be bound by a particular theory, it is believed that when the
 25 cytokine and at least portion of the receptor are administered in a combination, the at least portion of the receptor binds to the cytokine and thus alters the binding properties of the cytokine to receptors *in vivo*. Thus, in a presently preferred embodiment, the peptide binds to the cytokine.

The pharmaceutical composition may be in any form suitable for administration. In a preferred embodiment, the pharmaceutical composition is in a form suitable for injection.

The peptide of the pharmaceutical composition may comprise a sequence selected
5 from SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ
ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11
and SEQ ID No. 12, described below. The peptide of the pharmaceutical composition
may have at least 70% homology with any one of the peptides SEQ ID No. 1, SEQ ID
No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ
10 ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11 and SEQ ID No. 12, and be
capable of binding to the chemokine.

One or more amino acids in the peptide may be a steric enantiomer (D isomer), a
rare amino acid of plant origin, an unnatural amino acid or amino acid mimetic, or a
chemically modified amino acid. Such chemically modified amino acids are well-known
15 in the art and include amino acids modified by acetylation, acylation, phosphorylation,
dephosphorylation, glycosylation, myristoylation, amidation, aspartic acid/asparagine
hydroxylation, phosphopantethane attachment, methylation, methylthiolation, prenyl
group attachment, intein N- /C-terminal splicing, ADP-ribosylation, bromination,
citrullination, deamination, dihydroxylation, formylation, geranyl-geranilation, glycation,
20 or palmitoylation.

In another aspect, the present invention provides a pharmaceutical composition
comprising:

(a) a cytokine;

(b) a peptide selected from the group consisting of

25 (i) SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID
NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 10,
SEQ ID NO. 11, and SEQ ID NO. 12;

(ii) a peptide having at least 70% identity with any one of the peptides of (i);
and

(iii) a peptide of (i) or (ii) wherein at least one amino acid has been chemically modified; and

5 (c) a physiologically acceptable carrier;
wherein the peptide binds to the cytokine.

In another aspect, the invention provides use of the pharmaceutical composition of the invention for altering immune system functioning, for example in the treatment of an immune system disorder, including an autoimmune disease, multiple sclerosis, transplant
10 rejection, psoriasis and asthma.

In another aspect, the invention provides a method for preparing a pharmaceutical composition, the pharmaceutical composition comprising:

(a) a solubilized cytokine; and

(b) a solubilized peptide comprising at least a portion of a cytokine receptor or a
15 GPCR;

the method comprising combining the cytokine and the peptide *ex vivo*.

In another aspect, the present invention provides a method for preparing a pharmaceutical composition, the pharmaceutical composition comprising:

(a) a solubilized cytokine; and

20 (b) a solubilized peptide selected from the group consisting of

(i) SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 10, SEQ ID NO. 11, and SEQ ID NO. 12;

(ii) a peptide having at least 70% identity with any one of the peptides of (i)
25 capable of binding to a cytokine; and

(iii) a peptide of (i) or (ii) wherein at least one amino acid has been chemically modified;

the method comprising combining the cytokine and the peptide *ex vivo*.

In another aspect, the invention provides a peptide selected from:

(a) SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11 and SEQ ID No. 12;

5 (b) a peptide having at least 70% homology with a peptide of (a) capable of binding to a cytokine; and

(c) a peptide of (a) or (b) wherein at least one amino acid has been chemically modified.

10 In another aspect, the present invention provides a peptide selected from the group consisting of:

(a) SEQ ID NO.2, SEQ ID NO. 3, SEQ ID NO.4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 10, and SEQ ID NO. 11;

15 (b) a peptide having at least 70% identity with a peptide of (a) capable of binding to a cytokine; and

(c) a peptide of (a) or (b) wherein at least one amino acid has been chemically modified.

BRIEF DESCRIPTION OF THE DRAWINGS

20 In order to understand the invention and to see how it may be carried out in practice, embodiments will now be described, by way of non-limiting example only, with reference to the accompanying drawings, in which:

Fig. 1 shows chemokine binding of Chemokine Binding Peptide (CBP) 5;

Fig. 2 shows chemokine binding of CBP 8;

25 **Fig. 3** shows chemokine binding of CBP 10;

Fig. 4 shows chemokine binding CBP 2;

Fig. 5 shows chemokine binding of CBP 7;

Fig. 6 shows a negative control micro-array analyses in the absence of CBP5, CBP8, and CBP10 peptides (negative controls) that were performed in parallel with the binding experiment of Figs. 1, 2 and 3, respectively;

Fig. 7 shows a negative control micro-array analyses in the absence of CBP7, (negative control) that was performed in parallel with the binding experiment of Fig 5;

Fig. 8 shows a negative control micro-array analyses in the absence of CBP2, (negative control) that was performed in parallel with the binding experiment of Fig 4;

Fig. 9 shows chemokine binding of Phage-Presented Peptide (Ph-p) 11;

Fig. 10 shows chemokine binding of Ph-p 13;

Fig. 11 shows chemokine binding of Ph-p 15; **Fig. 12** shows chemokine binding of Ph-pl6;

Fig. 12 shows chemokine binding of Ph-p16;

Fig. 13 shows chemokine binding of Ph-p17;

Fig. 14 shows chemokine binding of Ph-p18;

Fig. 15 shows chemokine binding of Ph-p20;

Fig. 16 shows the effect of CBP 8 combined with the CK, MIG when administered to disease, Delayed Type Hypersensitivity (DTH), -induced mice;

Fig. 17 shows the effect of CBP 5 combined with the CK, RANTES when administered to disease, DTH-induced mice;

Fig. 18 shows the effect of CBP 8 combined with the CK, RANTES when administered to disease, DTH-induced mice;

Fig. 19 shows the effect of CBP 1 combined with the CK, MCP-1 when administered to disease, DTH-induced mice;

Fig. 20 shows the effect of CBP 5 combined with the CK, MCP-1 when administered to disease, DTH-induced mice;

Fig. 21 shows the effect of CBP-CK combinations CBP 1 - RANTES combined with CBP 8 - RANTES when administered to disease, DTH-induced mice; and

Fig. 22 shows the effect of the CBP–CK combinations, CBP 8 – IP-10 combined with CBP 8 - RANTES when administered to disease, DTH-induced mice.

EXAMPLES

5 MATERIALS AND METHODS

Chemokines (CKs): the following CKs were obtained from PreproTech Inc. (Rocky Hill, NJ USA)

Inflammatory CKs: (1) GRO- α (CXCL1 cat.no.300-11), (2) GRO- β (CXCL2 cat.no.300-39), (3) NAP-2 (CXCL7 cat.no.300-14), (4) IL-8(72aa) (CXCL8 cat.no.200-08M), (5) IL-8(77aa) (CXCL8 cat.no.200-08), (6) MIG (CXCL9 cat.no.300-26), (7) IP-10 (CXCL10 cat.no.300-12), (8) I-TAC (CXCL11 cat.no.300-46), (9) I-309 (CCL1 cat.no. 300-37), (10) MCP-1 (CCL2 cat.no.300-04), (11) MCP-2 (CCL8 cat.no. 300-15), (11) MCP-4 (CCL13 cat.no.300-24), (12) MIP-1 α (CCL3 cat.no.300-08), (13) MIP-1 α (CCL4 cat.no.300-09), (14) RANTES (CCL5 cat.no.300-06), (15) Eotaxin (CCL11 cat.no.300-21), (16) Eotaxin 2 (CCL24 cat.no.300-33), (17) Eotaxin 3(CCL26 cat.no.300-48).

Constitutive CKs: (1) TARC (CCL17 cat.no.300-30), (2) MDC(69aa), (CCL22 cat.no.300-36A), (3) SDF-1 α (CXCL12 cat.no.300-28a),

(4) SDF-1 β (CXCL12 cat.no.300-28b), (5) BCA-1 (CXCL13, cat.no.300-47), (6) MIP-3 α (CCL20 cat.no.300-29A), (7) MIP-3 β (CCL19 cat.no.300-29B), (8) Exodus-2 (CCL21 cat.no.300-35), (9) TECK (CCL25 cat.no.300-45), (10) CTAC (CCL27 cat.no.300-54).

Dual Function (Inflammatory and Constitutive) CKs: (1) Fractalkine (CX3CL1 cat.no.300-31), (2) Lymphotactin (XCL-1 cat.no.300-20), (3) PF-4 (CXCL4 cat.no.300-16).

The following 13 amino acid sequences were from CKR regulatory regions were used

SEQ ID No. 1: *SYDDVGL*, referred to herein as "*Peptide 1*". Origin: N- terminus of human C-C chemokine receptor type 3 (CCR3; Eosinophil Eotaxin receptor). The biotinylated peptide (N-terminus) was synthesized by BiomerTechnology, USA and dissolved in DMSO (0.05% in H₂O).

5 SEQ ID No. 2: *WVFGHGMCK*, referred to herein as "*Peptide 2*". Origin: Extra Cellular Loop (ECL)-2 of human C-C chemokine receptor type 3 (CCR3; Eosinophil Eotaxin receptor). The biotinylated peptide (N-terminus) was synthesized by Sigma, Israel and dissolved in H₂O.

10 SEQ ID No. 3: *LFGNDCE*, referred to herein as "*Peptide 5*". Origin: ECL-4 of human C-C chemokine receptor type 3 (CCR3; Eosinophil Eotaxin receptor). The biotinylated peptide (N-terminus) was synthesized by Sigma, Israel and dissolved in H₂O.

15 SEQ ID No. 4: *WVFGTFLCK*, referred to herein as "*Peptide 7*". Origin: ECL-2 of human C-C chemokine receptor type 2 (CCR2; Monocyte Chemoattractant Protein 1 receptor). The biotinylated peptide (N-terminus) was synthesized by BiomerTechnology, USA and dissolved in DMSO (0.1% in H₂O).

SEQ ID No. 5: *WVFGNAMCK*, referred to herein as "*Peptide 8*". Origin: ECL-2 of human C-C chemokine receptor type 2 (CCR2; Monocyte Chemoattractant Protein 1 receptor). The biotinylated peptide (N-terminus) was synthesized by BiomerTechnology, USA and dissolved in DMSO (0.1% in H₂O).

20 SEQ ID No. 6: *FFGLNNC*, referred to herein as "*Peptide 10*". Origin: ECL-4 of human C-C chemokine receptor type 5 (CCR5; HIV-1 Fusion Co-receptor). The biotinylated peptide (N-terminus) was synthesized by BiomerTechnology, USA and dissolved in DMSO (0.1% in H₂O).

25 SEQ ID No. 7: *TTFDYDYG*, referred to herein as "*Phage-presented (Ph) Peptide 11*". Origin: N-terminus of human C-C chemokine receptor type 2 (CCR2; Monocyte Chemoattractant Protein 1 receptor). The recombinant peptide was cloned in and expressed by the M13 cloning vector.

SEQ ID No. 8: *EDSVY*, referred to herein as "*Ph-Peptide 13*". Origin: ECL-3 of human C-C chemokine receptor type 2 (CCR2; Monocyte Chemoattractant Protein 1 receptor). The recombinant peptide was cloned in and expressed by the M13 cloning vector.

5 SEQ ID No. 9: *WVFGSGLCK*, referred to herein as "*Ph-Peptide 15*". Origin: ECL-2 of human C-X-C chemokine receptor type 2 (CXCR3; Interferon-inducible protein 10 receptor). The recombinant peptide was cloned in and expressed by the M13 cloning vector.

10 SEQ ID No. 10: *HHTCSLHFP*, referred to herein as "*Ph-Peptide 16*". Origin: ECL-3 of human C-C chemokine receptor type 1 (CCR1; Macrophage inflammatory protein 1-alpha receptor). The recombinant peptide was cloned in and expressed by the M13 cloning vector.

15 SEQ ID No. 11: *HYTCSSHFP*, referred to herein as "*Ph-Peptide 17*". Origin: ECL-3 of human C-C chemokine receptor type 5 (CCR5; HIV-1 Fusion Co-receptor). The recombinant peptide was cloned in and expressed by the M13 cloning vector.

SEQ ID No. 12: *DRYLNIVHAT*, referred to herein as "*Ph-Peptide 18*". Origin: ECL-3 of human C-X-C chemokine receptor type 3 (CXCR3; Interferon-inducible protein 10 receptor). The recombinant peptide was cloned in and expressed by the M13 cloning vector.

20 SEQ ID No. 13: *TKCQKE*, referred to herein as "*Ph-Peptide 20*". Origin: ECL-3 of human C-C chemokine receptor type 2 (CCR2; Monocyte Chemoattractant Protein 1 receptor). The recombinant peptide was cloned in and expressed by the M13 cloning vector.

25 **Micro-Array analysis of Chemokine Binding Peptides**

(1) **Printing:** Chemokine (CK) solution (in water) was serially diluted with Print Reagent (GenTel BioSurfaces USA) to final concentrations of 50 and 25 g/ml. BSA (Amresco, Cat.No.0032-256)/BSA-Biotin (Sigma, Cat.No.A8549) control solutions (in water)

were diluted with Print Reagent to 100ug/ml. An automated spotting robot (16 pin print tool, 0.4mm head; *BioRobotics*, UK) was used to print the CK/BSA control, 5 repeats per sample (25 µg/ml and 50µg/ml), on PATH Protein Microarray Slides (GenTel, Prod.No.2-1005/-1025) at 20⁰–30⁰C, and 50–70% relative humidity. Printed micro-array slides were stored at Room.Temperature or 4°C for at least 24h before use.

(2) ; **Blocking:** Block Buffer (500µl/partition; *PATHblock*, GenTel, Prod.No.2-1014) was applied to the slide for 1 hour at room temp (RT). After removal of Block Buffer, the slide was air dried for 25 minutes;

10 (3) **Peptide Binding:** The peptide was applied in Wash Buffer, 300µl (GenTel, *PATHwash*, Prod.No.2-1016), per partition and incubated at RT for 1 hour with gentle agitation;

(4) **Washing:** The slides were washed twice with Wash Buffer (300µl/partition);

15 (5) **First Label Binding:** The slides were incubated while protected from direct light with Cy3-labeled streptavidin (1mg/ml, 300µl/partition; DyLight 547, Pierce Prod.No.21424) for 45 minutes at RT;

(6) **First Washing:** The slides were washed twice with Wash Buffer (300µl/partition);

(7) **Second Label Binding:** Step (5) was repeated;

(8) **Second Washing:** Step (6) was repeated;

20 (9) **Rinse:** the slides were rinsed twice with Rinse Buffer (*PATHrinse*, GenTel, Prod.No.2-1018) then dried well;

(10) **Scanning:** The peptide-bound, labeled slide was scanned (Laser Intensity 60%, Gain 80%, Resolution 10µm) with a ScanArray Life Scanner (Packard BioChip Technologies, USA);

25 **Analysis:** Quantitative analysis of micro-array was performed by the SpotReader program of Niles Scientific (USA) and presented as Relative Fluorescence (RF) as a function of CK concentration. Micro-array readout (Cy3 fluorescence) was quantified to

determine the relative binding affinities of a CBP for the CKs and by inference, the specificity of the CBP for binding to a CK.

Micro-Array analysis of Phage Presented Chemokine Binding Peptides

5 **(1)Printing:** Chemokine (CK) solution (in water) was serially diluted with Print Reagent (GenTel BioSurfaces USA) to final concentrations of 50µg and 25µg/ml. BSA/BSA-Biotin control solutions (in water) were diluted with Print Reagent to 100µg/ml. Amplified stock of M13 phage control (M13KEgIII Cloning Vector, New England Biolabs, Cat.No.E8101S) was stored in Tris Buffered Saline (TBS; pH7.5, 4°C) and
10 diluted with Print Reagent to the working titre (10^8 pfu/µl). An automated spotting robot (16 pin print tool, 0.4mm head; *BioRobotics*, UK) was used to print the CK/BSA control/M13 control, 5 repeats per sample (CK 25 µg/ml and 50µg/ml; BSA 100µg/ml; M13 20µl), on PATH Protein Microarray Slides (GenTel, Prod.No.2-1005/-1025) at 20⁰–30⁰C, and 50–70% relative humidity. Printed micro-array slides were stored at
15 Room.Temperature or 4°C for at least 24h before use.

(2) Blocking: Block Buffer (500µl/partition; *PATHblock*, GenTel, Prod.No.2-1014) was applied to the slide for 1 hour at room temp (RT). After removal of Block Buffer, the slide was air dried for 25 minutes;

(2) Phage Presented Peptide Binding: Amplified recombinant phage stock was stored
20 in TBS and diluted with Wash Buffer to working titer (10^7 pfu/µl). Recombinant phage suspension (300µl) was applied per partition and incubated at RT for 1 hour with gentle agitation.

(3) First Washing: The slides were washed twice with Wash Buffer (300µl/partition);

(4) Primary Antibody (Ab) Labeling: The slides were incubated with the Primary Ab
25 (1mg/ml diluted x2500 (Wash Reagent), 300µl; Mouse Anti-M13 monoclonal Ab; Amersham Biosciences, UK; Product Code 27-9420-01) for 45 minutes at RT;

(5) Second Washing: The slides were washed twice with Wash Buffer (300µl/partition);

- (6) **Secondary Ab Labeling:** The slides were incubated with Secondary Ab (1.5mg/ml diluted x5000 (Wash Reagent), 300µl; Cy3-conjugated AffiniPure Goat Anti-Mouse IgG; Jackson ImmunoResearch Labs, USA; Product Code 115-165-062).
- (7) **Third Washing:** The slides were washed twice with Wash Buffer (300µl/partition);
- 5 (8) **Rinse:** the slides were rinsed twice with Rinse Buffer (PATHrinse, GenTel, Prod.No.2-1018) then dried well;
- (9) **Scanning:** The peptide-bound, labeled slide was scanned (Laser Intensity 80%, Gain 80%, Resolution 10µm) with a ScanArray Life Scanner (Packard BioChip Technologies, USA);
- 10 (10) **Analysis:** Quantitative analysis of micro-array was performed by the SpotReader program of Niles Scientific (USA) and presented as Relative Fluorescence (RF) as a function of CK concentration. Micro-array readout (Cy3 fluorescence) was quantified to determine the relative binding affinities of a CBP for the CKs and by inference, the specificity of the CBP for binding to a CK.

15

CK-Peptide Combination

Test samples which comprised specific combinations of CKs and Peptides were prepared by mixing the CK and Peptide in a tube and storing the mixture on ice for 1 hour

20 to 3 hours before injection into an experimental animal.

Anti-Inflammatory Control Reagent

Dexamethasone Sodium Phosphate (Dexacort Forte, Teva) was dissolved in **Phosphate Buffer Saline (PBS, GIBCO)** to a final concentration of 1mg/ml and

25 **injected in 200µl (200µg).**

The Animal Model of Disease (general inflammation): Delayed Type Hypersensitivity

Delayed-type hypersensitivity (DTH) reactions are antigen-specific, cell-mediated immune responses that, depending on the antigen, mediate beneficial (e.g. resistance to viruses, bacteria and fungi), or harmful (e.g. allergic dermatitis and autoimmunity) aspects of immune function. They are commonly used as models of chronic inflammatory diseases, since they are both initiated by an antigen and perpetuated by antigen-specific T cells.

Peptides were tested in a mouse model for their anti- or pro-inflammatory effects.

Contact hypersensitivity (CHS) reaction in mice differs from typical skin-irritation models, in that, an agent such as oxazolone (4-ethoxymethylene-2-oxazolin-5-one) is used which is not a strong irritant and requires a sensitization exposure before challenge. The role of oxazolone-specific T cells has been demonstrated by the ability of purified T cells from sensitized donor mice to transfer reactivity into naïve recipients [Asherson, 1968] and both CD4⁺ and CD8⁺ T cells are required to initiate the inflammatory response and recruit additional leukocytes [Gocinski, 1990].

Sensitization: Animals (BalbC, female, age 7-8 weeks, 5 per group) were sensitized by application of oxazolone (Sigma E0753, 100µl (2% (wt/vol) in oil (Kodak)) on abdominal skin, day 0.

Challenge: The animals were challenged by application of oxazolone (10µl (0.5% (wt/vol) in oil) to the left ear. 10µl of the carrier (oil) was applied to the right ear, on day 6.

Treatment: The test reagents (CK, Peptide, CK-Peptide combinations, Anti-Inflammatory Control) were prepared from frozen stocks (-20⁰C) on the day of the treatment and stored on ice until injected intra-peritoneally (0.2ml per injection), one hour before Challenge and one hour after Challenge.

Measurement: Ear thickness was measured with a dial thickness gauge (Mitutoyo, Japan) twenty four hours after challenge, on day 7. The pro- and anti-inflammatory activities of individual peptides and CKs and complexes of peptides with CKs, were calculated relative to the anti-inflammatory activity of Dexamethasone (Dexa).
 5 Dexa is an anti-inflammatory standard which, in this example, reduced measured inflammation by 36% and served as a standard of 100% for calculated values of the pro- and anti-inflammatory activities of the test reagents. An anti-inflammatory effect was measured as a reduction in inflammation compared with the untreated group of animals and its value calculated relative to the efficacy of Dexa (100% anti-inflammatory effect).
 10 A pro-inflammatory effect was measured as an increase in inflammation compared with the untreated group and its value calculated relative to Dexa.

RESULTS

15 **Micro-array analysis of Chemokine Binding Peptide 5 (CBP5) to inflammatory, constitutively expressed and dual function CKs.** Fig. 1 shows the binding affinity of CBP5 to several chemokines. CBP5 bound with relatively high affinity (>3000 Relative Fluorescence Units (RFU), responses in the upper 75% range of 0-12000 RFUs) to the inflammatory CKs, Eotaxin, Eotaxin 3, MCP-4 and RANTES, cognate CK
 20 ligands of the receptor from which CBP5 is derived. The same peptide bound with relatively high affinity to IL-8, MIG, I-309, MCP-1 and TARC, unrelated inflammatory CK ligands of the CKR, CCR3. CBP5 also bound the constitutively expressed CKs, SDF1- α/β , MIP3- α and TECK and the dual function CK, Fractalkine, none of which is a cognate ligand of the CKR, CCR3.

25 **Micro-array analysis of Chemokine Binding Peptide 8 (CBP8) binding to inflammatory, constitutively expressed and dual functions CKs.** As shown in Fig. 2, CBP8 bound with relatively high affinity (>1500 Relative Fluorescence Units (RFU), responses in the upper 75% range of 0-6000 RFUs) to the inflammatory CKs, MCP-1 and

-4, cognate CK ligands of the receptor from which CBP8 was derived. The same peptide bound with relatively high affinity to MIG, I-309, Eotaxin, Eotaxin 3, and to the constitutively expressed CKs, SDF1- β , BCA-1, Exodus-2, TECK, and the dual function CK, Fractalkine, all of which are unrelated CK ligands of the CKR from which CBP8 is
 5 derived.

Micro-array analysis of Chemokine Binding Peptide 10 (CBP10) binding to inflammatory, constitutively expressed and dual functions CKs. As shown in Fig. 3, CBP10 bound with relatively high affinity (>5000 Relative Fluorescence Units (RFU), responses in the upper 75% range of 0-20000 RFUs) to the inflammatory CK, MCP2,
 10 cognate ligand of the CKR from which CBP10 is derived. The same peptide bound with relatively high affinity to the inflammatory CKs, GRO- β , IP-10, I-TAC, I-309, MCP-1, -4, Eotaxin, Eotaxin 2/3 and to the constitutively expressed CKs, SDF1- α ,/ β BCA-1 Exodus-2 and TECK, and the dual function CKs, Fractalkine and Lymphotactin, all of
 15 which are unrelated CK ligands of the CKR from which CBP10 is derived.

CBP2 (*WVFGHGMCK*; from the Extra Cellular Loop (ECL)-2 of human C-C CKR type 3 (CCR3)) CBP2 was screened against the human inflammatory CKs, IL-8(72aa; CXCL8), MIG (CXCL9), I-309 (CCL1), MCP-1 (CCL2), MIP-1 α (CCL3),
 20 RANTES (CCL5), (15) Eotaxin (CCL11), Eotaxin 2 (CCL24), Eotaxin 3 (CCL26), TARC (CCL17), the human constitutive CKs, SDF-1 α (CXCL12), SDF-1 β (CXCL12), MIP-3 α (CCL20) and the CK, PF-4 (CXCL4). The results are shown in figs. 4A/B. Experimental readout (Cy3 fluorescence) was quantified to determine the relative binding affinities of CBPs for the CKs and by inference, the binding specificity of CBPs for the
 25 CKs. CBP2 bound with relatively high affinity (>10000 Relative Fluorescence Units (RFU), responses in the upper 75% range of 0-60000 RFUs) to the inflammatory CKs, Eotaxin and Eotaxin 3, cognate CK ligands of the receptor from which CBP2 is derived. The same peptide bound with relatively high affinity to the inflammatory CKs, MIG and

I-309 and the constitutively expressed CKs, SDF1- α/β and MIP3- α , all of which are unrelated CK ligands of the CKR from which CBP2 is derived.

CBP2, derived from ECL-2 of the CKR, CCR3, bound with relatively high affinity to Eotaxin 3, cognate CK ligand of the receptor. CBP2 interaction with Eotaxin 3 is consistent with the physiological interaction of a CK with its cognate receptor. The same peptide bound with relatively high affinity to MIG and I-309, unrelated inflammatory CK ligands of the CKR, CCR3. CBP2 also bound the constitutively expressed CKs, SDF1- α/β and MIP3- α , none of which is a cognate ligand of the CKR, CCR3. It is inferred from the latter observation that the unrelated inflammatory and constitutive CKs modify CCR2 activity by interacting with CBP2 sequence, in the structural context of the CKR, CCR3. Independent of its native CKR, CBP3 is a potential modulator of CK activity, that of cognate and unrelated CK ligands of the CKR, CCR3.

CBP7 (*WVFGTFLCK*; from ECL-2 of human C-C chemokine receptor type 2 (CCR2)) Peptide 7 (CBP7) was screened against the human inflammatory CKs, IL-8(72aa; CXCL8), MIG (CXCL9), IP-10 (CXCL10), I-TAC (CXCL11), I-309 (CCL1), MCP-1 (CCL2), MIP-1 α (CCL3), RANTES (CCL5), Eotaxin (CCL11), Eotaxin 2 (CCL24), Eotaxin 3 (CCL26), TARC (CCL17), the human constitutive CKs, SDF-1 α (CXCL12), SDF-1 β (CXCL12), MIP-3 α (CCL20) and the CK of undefined function, PF-4 (CXCL4) presented in micro-array format. The experimental readout (Cy3 fluorescence) was quantified to determine the relative binding affinities of the CBP for the CKs and by inference, the binding specificity of CBP7 for the CKs.

The results are shown in Fig. 5. CBP7 bound with relatively high affinity (>2000 Relative Fluorescence Units (RFU), responses in the upper 75% range of 0-10000 RFUs) to the inflammatory CKs I-309, Eotaxin and Eotaxin 3 and to the constitutively expressed CKs, SDF1- α and - β , none of which is a cognate CK ligand of the CKR from which CBP7 is derived.

Negative Control Micro-array analyses for Chemokine Binding Peptides to inflammatory, constitutively expressed and dual function CKs. Micro-array analyses in the absence of peptide (negative controls) were performed in parallel with analyses in the presence of peptide. Negative control results for CBP5, -8, and 10 are shown in Fig. 6. Negative control results for CBP7 are shown in Fig. 7. Negative control results for CBP2 are shown in Figures 8A and 8B.

Micro-array analysis of Phage-Presented Peptide, Ph-p11, binding to inflammatory, constitutively expressed and dual functions CKs. As shown in Fig. 9, Ph-p11 bound with relatively high affinity (>5000 Relative Fluorescence Units (RFU), responses in the upper 75% range of 0-20000 RFUs), to the inflammatory CKs, MCP-1, -2 and -4, cognate CK ligands of the receptor from which the peptide of Ph-p11 was derived. The same peptide bound with relatively high affinity to the inflammatory CKs, GRO- β , MIG, RANTES, Eotaxin, Eotaxin 3 and to the constitutively expressed CK, TECK, and the dual function Lymphotactin, all of which are unrelated CK ligands of the CKR from which the peptide of Ph-p11 is derived. The RFU values of the recombinant phage were calculated by deducting the RFU value of the phage by itself (negative control).

Micro-array analysis of Phage-Presented Peptide, Ph-p13, binding to inflammatory, constitutively expressed and dual functions CKs. As shown in Fig. 10, Ph-p13 bound with relatively high affinity (>1500 Relative Fluorescence Units (RFU), responses in the upper 75% range of 0-6000 RFUs) to the inflammatory CK, MCP-4, cognate CK ligand of the receptor from which the peptide of Ph-p13 was derived. The same peptide bound with relatively high affinity to the inflammatory CKs, GRO- β , Eotaxin, Eotaxin 3 and to the constitutively expressed CK, TECK, all of which are unrelated CK ligands of the CKR from which the peptide of Ph-p13 is derived. The RFU

values of the recombinant phage were calculated by deducting the RFU value of the phage by itself (negative control).

Micro-array analysis of Phage-Presented Peptide, Ph-p15, binding to inflammatory, constitutively expressed and dual functions CKs. As shown in Fig. 11, Ph-p15 bound with relatively high affinity (>30000 Relative Fluorescence Units (RFU), responses in the upper 50% range of 0-60000 RFUs) to the inflammatory CKs, MIG, IP-10 and I-TAC, cognate CK ligands of the receptor from which the peptide of Ph-p15 was derived. The same peptide bound with relatively high affinity to the inflammatory CKs, GRO- β , IL-8 (77), MCP1/2/4, RANTES, Eotaxin, Eotaxin 2, Eotaxin 3 and to the constitutively expressed CKs, BCA-1, Exodus 2 and TECK and the dual function CKs, Fractalkine and Lymphotactin, all of which are unrelated CK ligands of the CKR from which the peptide of Ph-p15 is derived. The RFU values of the recombinant phage were calculated by deducting the RFU value of the phage by itself (negative control).

15

Micro-array analysis of Phage-Presented Peptide, Ph-p16, binding to inflammatory, constitutively expressed and dual functions CKs. As shown in Fig. 12, Ph-p16 bound with relatively high affinity (>30000 Relative Fluorescence Units (RFU), responses in the upper 50% range of 0-60000 RFUs) to the inflammatory CKs, MCP-4 and RANTES, cognate CK ligands of the receptor from which the peptide of Ph-p16 was derived. The same peptide bound with relatively high affinity to the inflammatory CKs, GRO- β , MIG, MCP1/2, Eotaxin, Eotaxin 2, Eotaxin 3 and to the constitutively expressed CKs, BCA-1, Exodus 2 and TECK and the dual function CKs, Fractalkine and Lymphotactin, all of which are unrelated CK ligands of the CKR from which the peptide of Ph-p16 is derived. The RFU values of the recombinant phage were calculated by deducting the RFU value of the phage by itself (negative control).

25

Micro-array analysis of Phage-Presented Peptide, Ph-p17, binding to inflammatory, constitutively expressed and dual functions CKs. As shown in Fig. 13, Ph-p17 bound with relatively high affinity (>4500 Relative Fluorescence Units (RFU), responses in the upper 75% range of 0-22000 RFUs) to the inflammatory CKs, MCP-2 and RANTES, cognate CK ligands of the receptor from which the peptide of Ph-p17 was derived. The same peptide bound with relatively high affinity to the inflammatory CKs, GRO- β , IL-8 (77), MIG, IP-10, I-TAC, MCP1/4, Eotaxin, Eotaxin 2 and Eotaxin 3 and to the constitutively expressed CKs, BCA-1, Exodus 2 and TECK and the dual function CK Lymphotactin, all of which are unrelated CK ligands of the CKR from which the peptide of Ph-p17 is derived. The RFU values of the recombinant phage were calculated by deducting the RFU value of the phage by itself (negative control).

Micro-array analysis of Phage-Presented Peptide, Ph-p18, binding to inflammatory, constitutively expressed and dual functions CKs. As shown in Fig. 14, Ph-p18 bound with relatively high affinity (>6500 Relative Fluorescence Units (RFU), responses in the upper 75% range of 0-26000 RFUs) to the inflammatory CKs, MIG and I-TAC cognate CK ligands of the receptor from which the peptide of Ph-p18 was derived. The same peptide bound with relatively high affinity to the inflammatory CKs, GRO- β , IL-8 (72), IL-8 (77), MCP1/2/4, RANTES, Eotaxin, Eotaxin 2, Eotaxin 3 and to the constitutively expressed CKs, BCA-1, Exodus 2 and TECK and the dual function CKs, Fractalkine and Lymphotactin, all of which are unrelated CK ligands of the CKR from which the peptide of Ph-p18 is derived. The RFU values of the recombinant phage were calculated by deducting the RFU value of the phage by itself (negative control).

Micro-array analysis of Phage-Presented Peptide, Ph-p20, binding to inflammatory, constitutively expressed and dual functions CKs. As shown in Fig. 15, Ph-p20 bound with relatively high affinity (>12500 Relative Fluorescence Units (RFU), responses in the upper 75% range of 0-50000 RFUs) to the inflammatory CKs, MCP-1, -2

and -4, cognate CK ligands of the receptor from which the peptide of Ph-p20 was derived. The same peptide bound with relatively high affinity to the inflammatory CKs, GRO- β , IL-8 (72), IL-8 (77), IP-10, I-TAC, RANTES, Eotaxin, Eotaxin 3 and to the constitutively expressed CKs, BCA-1, Exodus 2 and TECK and the dual function CKs, Fractalkine and Lymphotactin, all of which are unrelated CK ligands of the CKR from which the peptide of Ph-p20 is derived. The RFU values of the recombinant phage were calculated by deducting the RFU value of the phage by itself (negative control).

Efficacy of the CK MIG (CXCL9), Peptide 8 and different doses of Peptide 8 combined with MIG. The CK MIG, is expressed at elevated levels in inflammatory conditions and defined as an inflammatory CK. As shown in Fig. 16, 200ng MIG, administered to disease induced mice was pro-inflammatory, increasing inflammation by 38% (-38 in Fig.16) compared with disease-induced, untreated animals. 1100ng Peptide 8 had a pro-inflammatory effect when administered to disease-induced mice, increasing inflammation by 44% (-44) compared with disease-induced, untreated animals. A combination of MIG and Peptide 8 had an anti-inflammatory effect when administered to the disease-induced animals. With a dose consisting of 20ng MIG and 100ng Peptide 8, the anti-inflammatory effect was 5% (5), compared with disease-induced, untreated animals. With a dose consisting of 100ng MIG: and 550ng Peptide 8, and with a dose consisting of 200ng MIG and 1000ng Peptide 8, the anti-inflammatory effect was 55% (55) and 14% (14), respectively. The molecular ratio of the respective doses was 1:50 (CK: Peptide).

Efficacy of the CK, RANTES (CCL5) and Peptide 5 and different doses of Peptide 5 combined with RANTES The CK RANTES, is expressed at elevated levels in inflammatory conditions and is classified as an inflammatory CK. As shown in Fig. 17, 200ng RANTES, administered to disease induced mice was slightly pro-inflammatory, increasing inflammation by <3% (<-3 in Fig.17) compared with disease-induced,

untreated animals. 1,300ng Peptide 5 had an anti-inflammatory effect when administered to disease-induced mice, decreasing inflammation by 11% (11) compared with disease-induced, untreated animals. A combination of RANTES and Peptide 5 had a pro-inflammatory effect of 18% (-18) when administered to the disease-induced animals at a dose consisting of 20ng RANTES and 130ng Peptide 5. At a dose consisting of 100ng RANTES and 550ng Peptide 5, the anti-inflammatory effect of the combination was 34% (34), compared with disease-induced, untreated animals. At a dose consisting of 200ng RANTES and 1300ng Peptide 5, the anti-inflammatory effect was 18% (18). The molecular ratio of the respective doses was 1:50 (CK:Peptide). Given the pro-inflammatory activity of RANTES alone and the anti-inflammatory activity of Peptide 5 by itself, the activities of the CK-Peptide combinations are evidence of formation of a RANTES-Peptide 5 complex and stability of the complex. At the sub-optimal dose (RANTES: 20ng – Peptide 5 130ng,) the complex manifested pro-inflammatory activity, consistent with the biphasic properties of CKs. At low concentrations, CKs are chemo-attractants, inducing target (inflammatory) cell migration. At relatively high concentrations CKs inhibit target cell migration. An optimal dose (RANTES: 100ng – Peptide 6: 550ng) was required for a maximal anti-inflammatory effect, consistent with the biological activity of a competitive inhibitor of a disease related, wild type CK. At the supra-optimal dose, the active complex activated disease non-related CK receptors inducing a counter-indicative, pro-inflammatory response.

Efficacy of the CK RANTES (CCL5), Peptide 8 and different doses of Peptide 8 combined with RANTES. Referring now to Fig. 18, as shown above, 200ng of the CK RANTES when administered to disease induced mice is pro-inflammatory, increasing inflammation by <3% (<-3 in Fig.18) compared with disease-induced, untreated animals. 1100ng Peptide 8 had a pro-inflammatory effect when administered to disease-induced mice, increasing inflammation by 44% (-44) compared with disease-induced, untreated animals. A combination of RANTES and Peptide 8 had an anti-inflammatory effect when

administered to the disease-induced animals at two doses, RANTES: 2ng and Peptide 8: 20ng (52% (52)) and RANTES: 10ng and Peptide 8: 100ng (25% (25)). With a dose of RANTES: 50ng and Peptide 8: 500ng, the pro-inflammatory effect was 36% (-36), compared with disease-induced, untreated animals. The molecular ratio of the respective
 5 doses was 1:50 (CK:Peptide). The pro-inflammatory activities of the individual components (RANTES and Peptide 8) and the anti-inflammatory activities of the CK-Peptide combinations are evidence of formation of a stable complex. Maximal anti-inflammatory activity was observed with the combination consisting of RANTES: 2ng and Peptide 8: 20ng , consistent with the biological activity of a competitive inhibitor of a
 10 disease related, wild type CK. At the supra-optimal doses, the active complex activated disease non-related CK receptors inducing a counter-indicative, pro-inflammatory response.

Efficacy of the CK MCP1 (CCL2), Peptide 1 and different doses of Peptide 1
 15 **combined with MCP1.** The CK MCP1, is expressed at elevated levels in inflammatory conditions and is classified as an inflammatory CK. As shown in Fig. 19, 200ng MCP1, administered to disease induced mice, was pro-inflammatory, increasing inflammation by 23% (-23 in Fig.19) compared with disease-induced, untreated animals. 1,400ng Peptide 1 had a pro-inflammatory effect when administered to disease-induced mice, increasing
 20 inflammation by 34% (-34) compared with disease-induced, untreated animals. A combination of MCP1 and Peptide 1 had a pro-inflammatory effect when administered to the disease-induced animals at two doses, MCP1: 20ng and Peptide 1: 140ng (55% (55)) and MCP1: 100ng and Peptide 1: 700ng (23% (23)). At a dose of MCP1: 200ng and Peptide 1: 1400ng, the anti-inflammatory effect was 33% (33), compared with disease-
 25 induced, untreated animals. The molecular ratio of the respective doses was 1:50, CK: Peptide. The pro-inflammatory activities of the individual components (MIG and Peptide 1) and the anti-inflammatory activity of the CK-Peptide combination is evidence of formation of a stable complex. At the sub-optimal doses (MCP1: 20ng – Peptide 1:

140ng; MCP1: 100ng – Peptide 1: 700ng) the complex manifested pro-inflammatory activity, consistent with the biphasic properties of CKs. At low concentrations CKs are chemo-attractants, inducing target (inflammatory) cell migration. At relatively high concentrations CKs inhibit target cell migration. An optimal dose (MCP1: 200ng and
 5 Peptide 1: 1400ng was required for the anti-inflammatory effect, consistent with the biological activity of a competitive inhibitor of a disease related, wild type CK.

Efficacy of the CK, MCP1 (CCL2), Peptide 5 and different doses of Peptide 5 combined with MCP1. The CK MCP1, is expressed at elevated levels in inflammatory
 10 conditions and is classified as an inflammatory CK. As shown in Fig. 20, 200ng MCP1, administered to disease induced mice was pro-inflammatory, increasing inflammation by 23% (-23 in Fig.20) compared with disease-induced, untreated animals. 1300ng Peptide 5 had an anti-inflammatory effect when administered to disease-induced mice, decreasing inflammation by 11% (11) compared with disease-induced, untreated animals. A
 15 combination of MCP1 and Peptide 5 had a pro-inflammatory effect when administered to the disease-induced animals at two doses, MCP1: 20ng and Peptide 5: 120ng (23% (-23)) and MCP1: 200ng and Peptide 5: 1200ng (11% (-11)). At a dose of MCP1: 100ng and Peptide 5: 600ng the anti-inflammatory effect was 79% (79), compared with disease-induced, untreated animals. The molecular ratio of the respective doses was 1:50, CK:
 20 Peptide. The pro-inflammatory activities of the individual components (MCP1 and Peptide 5) and the anti-inflammatory activity of the CK-Peptide combination is evidence of formation of a stable complex. At a sub-optimal dose (MCP1: 20ng – Peptide 5: 120ng) the complex manifested pro-inflammatory activity, consistent with the biphasic properties of CKs. At low concentrations, CKs are chemo-attractants, inducing target
 25 (inflammatory) cell migration. At relatively high concentrations CKs inhibit target cell migration. An optimal dose (MCP1: 100ng and Peptide 5: 600ng) was required for the anti-inflammatory effect, consistent with the biological activity of a competitive inhibitor of a disease related, wild type CK. At the supra-optimal dose, the active complex

activated disease non-related CK receptors inducing a counter-indicative, pro-inflammatory response.

Efficacies of the CK – Peptide combinations, RANTES (CCL5) – Peptide 1 and RANTES - Peptide 8, separately and together. As shown in Fig. 21, a dose consisting of a combination of 100 ng RANTES and 750 ng Peptide 1, administered to disease induced mice, was pro-inflammatory, increasing inflammation by 30% (-30 in Fig.21) compared with disease-induced, untreated animals. In contrast to this, a dose consisting of a combination of 10 ng RANTES and 100 ng Peptide 8 was anti-inflammatory, decreasing inflammation by 25% (25). The counter-indicative therapeutic activities of the respective RANTES – Peptide combinations, RANTES – Peptide 1 and RANTES – Peptide 8, was evidence that each of the peptides modulated RANTES activity in an opposite way and that each combination was a stable complex,. The net effect of administrating RANTES – Peptide 1 together with RANTES - Peptide 8 to disease-induced animals (38% (38) anti-inflammatory,) has implications for the pharmacological properties of the complexes. The net anti-inflammatory effect may be the consequence of competition between functionally discrete complexes for the same disease-related CK receptor or, alternatively, the result of activating functionally opposed, pro- and anti-inflammatory, receptors.

Efficacies of the CK – Peptide combinations, IP10 (CXCL10) – Peptide 8 and RANTES (CCL5) - Peptide 8, separately and together. A dose consisting of 100 ng IP10 and 750 ng Peptide 8, administered to the disease induced mice, was pro-inflammatory, increasing inflammation by 60% (-60 in Fig. 22) compared with disease-induced, untreated animals . A dose consisting of 10 ng RANTES and 100ng Peptide 8 was anti-inflammatory, decreasing inflammation by 25% (25). The counter-indicative therapeutic activities of these two CK – Peptide combinations is evidence that Peptide 8 modulated the inflammatory CK IP10 and RANTES activities in opposite ways. The net

anti-inflammatory effect may be the consequence of competition between functionally discrete complexes for the same disease-related CK receptor or, alternatively, the result of activating functionally opposed, pro- and anti-inflammatory, receptors.

5 **Therapeutic Indications**

Rheumatoid Arthritis Clinical observation and empirical evidence have indicated roles for RANTES, MIG, MCP-1 and IP10 and their respective cognate receptors, in the pathogenesis of Rheumatoid Arthritis [www.iddb3.com in Wells, 2006]. A combination
10 consisting of RANTES and CBP 5 (see Fig.17), RANTES and CBP 8 (see Fig.18), MIG and CBP 8 (see Fig.16), MCP-1 and CBP 1 (see Fig.19), MCP1 and CBP 5 (see Fig.20), or IP10 and CBP 8 (see Fig.22), may be used in the treatment of rheumatoid arthritis.

Asthma The CKs, RANTES and MCP-1 and the CK receptors, CCR3, origin of
15 CBP 1 and CBP 5 and CCR2, origin of CBP 8, are implicated in the pathogenesis of Asthma [www.iddb3.com in Wells, 2006]. A combination of RANTES and CBP 5 (see Fig.17), RANTES and CBP 8 (see Fig.18), MCP-1 and CBP 1 (see Fig.19), or MCP-1 and CBP 5 (see Fig.20), may be used in the treatment of Asthma.

Transplantation Rejection The levels of CKs, MIG, RANTES, MCP-1 and IP10
20 and the CK receptor, CCR2, origin of CBP 8, correlate with Organ Transplant Rejection (www.iddb3.com in Wells, 2006). A combination of MIG and CBP 8 (see Fig.16), RANTES and CBP 5 (see Fig.17), RANTES and CBP 8 (see Fig.18), MCP-1 and CBP 1 (see Fig.19), MCP1 and CBP 5 (see Fig.20), or IP10 and CBP 8 (see Fig.22), may be used
25 in the treatment of Transplant Rejection.

Multiple Sclerosis MIG, RANTES, MCP-1 and IP10 are Multiple Sclerosis-related CKs and the CK receptor, CCR2, origin of CBP 8, is implicated in the disease (www.iddb3.com in Wells, 2006). A combination of MIG and CBP 8 (see Fig.16), RANTES and CBP 5 (see Fig.17), RANTES and CBP 8 (see Fig.18), MCP-1 and CBP 1
 5 (see Fig.19), MCP1 and CBP 5 (see Fig.20), or IP10 and CBP 8 (see Fig.22), may be used in the treatment of Transplant Rejection.

Inflammatory Bowel Disease The CK, RANTES, is implicated in the pathogenesis of Inflammatory Bowel Disease (www.iddb3.com in Wells., 2006). A
 10 combination of RANTES and CBP 5 (see Fig.17), or RANTES and CBP 8 (see Fig.18) may be used in the treatment of the disease.

Psoriasis The CKs, MIG and RANTES are implicated in the pathogenesis of Psoriasis (www.iddb3.com in Wells, 2006). A combination of MIG and CBP 8 (see
 15 Fig.16), RANTES and CBP 5 (see Fig.17), or RANTES and CBP 8 (see Fig.18), may be used in the treatment of the disease.

AIDS The cognate receptor of RANTES, CCR5, is involved in HIV infection and a validated drug target for the treatment of AIDS (www.iddb3.com in Wells, 2006). A
 20 combination of RANTES and CBP 5 (see Fig.17), or RANTES and CBP 8 (see Fig.18), may be used as a competitive inhibitor of the virus in the treatment of the disease.

CANCER Metastasis and angiogenesis are essential for cancer pathogenesis. CKs mediate the cell migration of metastasis and the vascularization of angiogenesis. The
 25 CK – CBP combinations are potential modulators of and as such, therapeutic agents for, these pathogenic processes.

SEQUENCE LISTING IN ELECTRONIC FORM

In accordance with section 111(1) of the Patent Rules, this description contains a sequence listing in electronic form in
5 ASCII text format (file: 90993-24D2Tseq2018-06-22v1.txt).

A copy of the sequence listing in electronic form is available from the Canadian Intellectual Property Office.

10 The sequences in the sequence listing in electronic form are reproduced in the following table.

SEQUENCE TABLE

15 <110> SYMThERA CANADA LTD.

<120> COMBINATION OF CYTOKINE AND CYTOKINE RECEPTOR FOR ALTERING
20 IMMUNE SYSTEM FUNCTIONING

<130> 90993-24D2T

<150> CA 2,922,127
25 <151> 2007-03-18

<150> CA 2,646,931
<151> 2007-03-18

30 <150> US 60/782,689
<151> 2006-03-16

<160> 13
35

<170> PatentIn version 3.1

40 <210> 1

<211> 8

45 <212> PRT

<213> Homo sapiens

<400> 1

5 Ser Tyr Tyr Asp Asp Val Gly Leu
1 5

10 <210> 2

<211> 9

<212> PRT

15

<213> Homo sapiens

20 <400> 2

Trp Val Phe Gly His Gly Met Cys Lys
1 5

25

<210> 3

<211> 7

30

<212> PRT

<213> Homo sapiens

35

<400> 3

Leu Phe Gly Asn Asp Cys Glu
1 5

40

<210> 4

45 <211> 9

<212> PRT

<213> Homo sapiens

5

<400> 4

Trp Val Phe Gly Thr Phe Leu Cys Lys
1 5

10

<210> 5

15 <211> 9

<212> PRT

<213> Homo sapiens

20

<400> 5

25 Trp Val Phe Gly Asn Ala Met Cys Lys
1 5

30

<210> 6

<211> 7

35 <212> PRT

<213> Homo sapiens

40

<400> 6

Phe Phe Gly Leu Asn Asn Cys
1 5

45

<210> 7

<211> 9

5 <212> PRT

<213> Homo sapiens

10

<400> 7

Thr Thr Phe Phe Asp Tyr Asp Tyr Gly
1 5

15

<210> 8

20 <211> 5

<212> PRT

<213> Homo sapiens

25

<400> 8

30 Glu Asp Ser Val Tyr
1 5

35

<210> 9

<211> 9

40 <212> PRT

<213> Homo sapiens

45

<400> 9

Trp Val Phe Gly Ser Gly Leu Cys Lys
1 5

5

<210> 10

<211> 9

10 <212> PRT

<213> Homo sapiens

15

<400> 10

His His Thr Cys Ser Leu His Phe Pro
1 5

20

<210> 11

25 <211> 9

<212> PRT

<213> Homo sapiens

30

<400> 11

35 His Tyr Thr Cys Ser Ser His Phe Pro
1 5

40 <210> 12

<211> 10

<212> PRT

45

<213> Homo sapiens

<400> 12

5 Asp Arg Tyr Leu Asn Ile Val His Ala Thr
1 5 10

10 <210> 13

<211> 6

<212> PRT

15

<213> Homo sapiens

20 <400> 13

Thr Lys Cys Gln Lys Glu
1 5

25

CLAIMS:

1. A pharmaceutical composition comprising:
 - (a) a cytokine;
 - (b) a peptide comprising at least a portion of a cytokine receptor or a G-protein
5 coupled receptor (GPCR); and
 - (c) a physiologically acceptable carrier.
2. The pharmaceutical composition according to Claim 1 in a form suitable for injection.
3. The pharmaceutical composition according to Claim 1 or Claim 2 wherein the
10 cytokine is a chemokine.
4. The pharmaceutical composition according to any one of the previous claims wherein the receptor is a cytokine receptor.
5. The pharmaceutical composition according to Claim 4 wherein the cytokine receptor is a chemokine receptor.
- 15 6. The pharmaceutical composition according to any one of Claims 1 to 3 wherein the receptor is a GPCR receptor.
7. The pharmaceutical composition according to any one of the previous claims wherein the peptide binds to the cytokine.
8. The pharmaceutical composition according to any one of the previous claims
20 wherein the peptide comprises at least a portion of an extracellular domain of the cytokine receptor.
9. The pharmaceutical composition according to any one of the previous claims wherein the peptide comprises at least a portion of a regulatory sequence of the cytokine receptor.
- 25 10. The pharmaceutical composition according to any one of the previous claims wherein the cytokine is an inflammatory cytokine.
11. The pharmaceutical composition according to any one of Claims 1 to 10 wherein the cytokine is a constitutive cytokine.

12. The pharmaceutical composition according to any one of Claims 1 to 10 wherein the cytokine is a dual function cytokine.

13. The pharmaceutical composition according to any one of Claims 1 to 10 wherein the cytokine is selected from:

- 5 (a) GRO- α ;
- (b) GRO- β ;
- (c) NAP-2;
- (d) IL-8;
- (e) IL-8;
- 10 (f) MIG;
- (g) IP-10;
- (h) I-TAC;
- (i) I-309;
- (j) MCP-1;
- 15 (k) MCP-2;
- (l) MCP-4;
- (m) MIP-1;
- (n) MIP-1 α ;
- (o) RANTES;
- 20 (p) Eotaxin;
- (q) Eotaxin 2;
- (r) Eotaxin 3;
- (s) TARC;
- (t) MDC;
- 25 (u) SDF-1 α ;
- (v) SDF-1 β ;
- (w) BCA-1;
- (x) MIP-3 α ;

- (y) MIP-3 β ;
- (z) Exodus-2;
- (aa) TECK;
- (bb) CTAC;
- 5 (cc) Fractalkine;
- (dd) Lymphotactin; and
- (ee) PF-4.

14. The pharmaceutical composition according to any one of the previous claims wherein the peptide comprises a sequence selected from SEQ ID No. 1, SEQ ID No. 2, 10 SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11 and SEQ ID No. 12..

15. The pharmaceutical composition according to any one of Claim 7 wherein the peptide has at least 70% homology with any one of the peptides SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ 15 ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11 and SEQ ID No. 12.

16. The pharmaceutical composition according to anyone of the previous claims wherein one or more amino acids in the peptide is a chemically modified amino acid.

17. The pharmaceutical composition according to Claim 16 wherein one or more amino acids are a steric enantiomer (D isomer), a rare amino acid of plant origin, an 20 unnatural amino acid or amino acid mimetic, or have been modified by any one or more modifications selected from acetylation, acylation, phosphorylation, dephosphorylation, glycosylation, myristollation, amidation, aspartic acid/asparagine hydroxylation, phosphopantethane attachment, methylation, methylthiolation, prenyl group attachment, intein N-/C-terminal splicing, ADP-ribosylation, bromination, citrullination, deamination, 25 dihydroxylation, formylation, geranyl-geranilation, glycation, and palmitoylation.

18. Use of the pharmaceutical composition according to any one of the previous claims for altering immune system functioning.

19. The use according to Claim 18 for the treatment of an immune system disorder.

20. The use according to Claim 19 wherein the immune system disorder is selected from an autoimmune disease, multiple sclerosis, transplant rejection, psoriasis and asthma.
21. A method for treating an immune system disorder comprising administering to an individual in need of such treatment a pharmaceutical composition comprising:
- (a) A cytokine;
 - (b) A peptide comprising at least a portion of a cytokine receptor or a GPCR; and
 - (c) A physiologically acceptable carrier.
22. The method according to Claim 21 in a form suitable for injection.
23. The method according to Claim 21 or 22 wherein the cytokine is a chemokine.
24. The method according to any one of Claims 21 to 23 wherein the receptor is a cytokine receptor.
25. The method according to Claim 24 wherein the cytokine receptor is a chemokine receptor.
26. The method according to any one of Claims 21 to 23 wherein the receptor is a GPCR.
27. The method according to any one of Claims 21 to 26 wherein the peptide binds to the cytokine.
28. The method according to any one of Claims 21 to 27 wherein the peptide comprises at least a portion of an extracellular domain of the receptor.
29. The method according to any one of Claims 27 or 28 wherein the peptide comprises at least a portion of a regulatory sequence of the receptor.
30. The method according to Claims 21 to 29 wherein the cytokine is an inflammatory cytokine.
31. The method according to any one of Claims 21 to 29 wherein the cytokine is a constitutive cytokine.
32. The method according to any one of Claims 21 to 29 wherein the cytokine is a dual function cytokine.

33. The method according to any one of Claims 21 to 29 wherein the cytokine is selected from:

- (a) GRO- α ;
- (b) GRO- β ;
- 5 (c) NAP-2;
- (d) IL-8;
- (e) IL-8;
- (f) MIG;
- (g) IP-10;
- 10 (h) I-TAC;
- (i) I-309;
- (j) MCP-1;
- (k) MCP-2;
- (l) MCP-4;
- 15 (m) MIP-1;
- (n) MIP-1 α ;
- (o) RANTES;
- (p) Eotaxin;
- (q) Eotaxin 2;
- 20 (r) Eotaxin 3;
- (s) TARC;
- (t) MDC;
- (u) SDF-1 α ;
- (v) SDF-1 β ;
- 25 (w) BCA-1;
- (x) MIP-3 α ;
- (y) MIP-3 β ;
- (z) Exodus-2;

- (aa) TECK;
- (bb) CTAC;
- (cc) Fractalkine;
- (dd) Lymphotactin; and
- 5 (ee) PF-4.

34. The method according to any one of Claims 21 to 33 wherein the peptide comprises a sequence selected from SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11 and SEQ ID No. 12..

10 35. The method according to Claim 27 wherein the peptide has at least 70% homology with any one of the peptides SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11 and SEQ ID No. 12.

36. The method according to anyone of Claims 21 to 35 wherein one or more amino
15 acids in the peptide is a chemically modified amino acid.

37. The method according to Claim 36 wherein one or more amino acids have been modified by any one or more modifications selected from acetylation, acylation, phosphorylation, dephosphorylation, glycosylation, myristollation, amidation, aspartic acid/asparagine hydroxylation, phosphopantethane attachment, methylation,
20 methylthiolation, prenyl group attachment, intein N-/C-terminal splicing, ADP-ribosylation, bromination, citrullination, deamination, dihydroxylation, formylation, geranyl-geranilation, glycation, and palmitoylation.

38. The method according to any one of Claims 21 to 37 wherein the immune system disorder is selected from an autoimmune disease, multiple sclerosis, transplant rejection,
25 psoriasis and asthma.

39. A method for preparing a pharmaceutical composition, the pharmaceutical composition comprising:

- (a) a solubilized cytokine; and

- (b) a solubilized peptide comprising at least a portion of a cytokine receptor or a GPCR;

the method comprising combining the cytokine and the peptide ex vivo.

40. The method according to Claim 40 further comprising incubating the combination
5 for a predetermined amount of time.

41. A peptide selected from:

- (a) SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5,
SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10,
SEQ ID No. 11 and SEQ ID No. 12;

10 (b) a peptide having at least 70% homology with a peptide of (a) capable of
binding to a cytokine; and

- (c) a peptide of (a) or (b) wherein at least one amino acid has been chemically
modified.

15

20

25

1/19




Figure 1

SUBSTITUTE SHEET (RULE 26)

2/19





Figure 2

SUBSTITUTE SHEET (RULE 26)

3/19



4/19




Figure 4A




Figure 4B

SUBSTITUTE SHEET (RULE 26)

5/19





Figure 5

SUBSTITUTE SHEET (RULE 26)

6/19



7/19




Figure 7

SUBSTITUTE SHEET (RULE 26)

8/19




Figure 8A




Figure 8B

SUBSTITUTE SHEET (RULE 26)

9/19




Figure 9

SUBSTITUTE SHEET (RULE 26)

10/19



Figure 10

SUBSTITUTE SHEET (RULE 26)

11/19




Figure 11

12/19




Figure 12

SUBSTITUTE SHEET (RULE 26)

13/19




Figure 13

14/19




Figure 14

15/19




Figure 15

SUBSTITUTE SHEET (RULE 26)

16/19




Figure 16




Figure 17

SUBSTITUTE SHEET (RULE 26)

17/19




Figure 18




Figure 19

SUBSTITUTE SHEET (RULE 26)

18/19




Figure 20




Figure 21

SUBSTITUTE SHEET (RULE 26)

19/19




Figure 22

SUBSTITUTE SHEET (RULE 26)